Bcps
Impact in
- Internal Medicine top 1%
- Venous Thromboembolism Diagnosis and Management
-
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
Papers in
-
- Atrial Fibrillation Management and Outcomes 4
- Oncology 6
- Cancer Treatment and Pharmacology 3
- Co-authors
- Anna D. Garrett (3 shared papers)J Bourret (2 shared papers)Kate M. O’Dell (2 shared papers)Erica Tavares (1 shared paper)Diana M Sobieraj (5 shared papers)Jennifer N. Clements (1 shared paper)Joseph Bubalo (3 shared papers)Margarita V. DiVall (1 shared paper)
- Journals
- Journal of Oncology Practice (1 paper)The Psychiatric times (1 paper)
- Partner nations
- United States
In The Last Decade
Bcps
34 papers receiving 991 citations
Bcps's Hit Papers
Peers
Comparison fields: 5 of 72
- Internal Medicine 423
- Cardiology and Cardiovascular Medicine 673
- Critical Care and Intensive Care Medicine 39
- Neurology 97
- Hematology 70
Countries citing papers authored by Bcps
This map shows the geographic impact of Bcps's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bcps with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bcps more than expected).
Fields of papers citing papers by Bcps
This network shows the impact of papers produced by Bcps. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bcps. The network helps show where Bcps may publish in the future.
Co-authors
The 23 scholars most cited alongside Bcps, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Idarucizumab for dabigatran reversal Hit paper breakdown → | 2015 | 923 |
| 2 | Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured Population | 2014 | 29 |
| 3 | Treatment of rheumatoid arthritis: A review of recommendations and emerging therapy | 2011 | 7 |
| 4 | Fluorouracil Overdose: Clinical Manifestations and Comprehensive Management During and After Hospitalization | 2015 | 7 |
| 5 | Tofacitinib: A novel oral Janus kinase inhibitor for rheumatoid arthritis | 2012 | 4 |
| 6 | Emotional Impact of Venous Thromboembolism: A Qualitative Study of Patients’ Journeys | 2017 | 3 |
| 7 | Evaluating the Effects of a 14-Day Oral Chemotherapy Dispensing Protocol on Adherence, Toxicity, and Cost | 2015 | 3 |
| 8 | Linaclotide: A guanylate cyclase type-C agonist for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation | 2012 | 3 |
| 9 | Monitoring Methotrexate Levels in a Patient After Glucarpidase Administration: A Case Report | 2020 | 3 |
| 10 | Palonosetron: A novel 5-HT3 receptor antagonist for chemotherapy-associated nausea and vomiting | 2003 | 3 |
| 11 | HER2 Receptor Antagonist–Associated Cardiotoxicity | 2016 | 3 |
| 12 | Adult ADHD: A Review of the Clinical Presentation, Challenges, and Treatment Options | 2015 | 2 |
| 13 | Dabigatran vs. warfarin in patients with mechanical heart valves | 2013 | 2 |
| 14 | Fingolimod: A potential first-in-class oral therapy for the treatment of relapsing-remitting multiple sclerosis | 2010 | 2 |
| 15 | Blinatumomab: A Step Forward in the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia | 2019 | 2 |
| 16 | FDA approves first SGLT2 inhibitor for T2DM | 2013 | 2 |
| 17 | Spotlight on pharmaceutical pipeline database products : A useful resource for PBMs and MCOs | 2008 | 2 |
| 18 | Achieving Remission in Generalized Anxiety Disorder | 2009 | 2 |
| 19 | Prescribing of Low-Molecular-Weight Heparin and Warfarin in Patients with Acute Venous Thromboembolism and Active Cancer | 2015 | 1 |
| 20 | Apixaban: An orally active factor Xa inhibitor to prevent strokes and systemic embolism in patients with nonvalvular atrial fibrillation | 2012 | 1 |
About Bcps
Bcps is a scholar working on Cardiology and Cardiovascular Medicine, Oncology, Surgery, Pediatrics, Perinatology and Child Health and Geriatrics and Gerontology, having authored 50 papers that have together received 1.0k indexed citations. Recurring topics across this work include Pharmaceutical studies and practices (5 papers), Pharmaceutical Practices and Patient Outcomes (5 papers), Atrial Fibrillation Management and Outcomes (4 papers), Venous Thromboembolism Diagnosis and Management (4 papers), Attention Deficit Hyperactivity Disorder (3 papers), Cancer Treatment and Pharmacology (3 papers), Gastrointestinal motility and disorders (2 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). The work is most often cited by research in Internal Medicine (423 citations), Cardiology and Cardiovascular Medicine (673 citations), Critical Care and Intensive Care Medicine (39 citations), Neurology (97 citations) and Hematology (70 citations). Bcps has collaborated with scholars based in United States. Frequent co-authors include Anna D. Garrett, J Bourret, Kate M. O’Dell, Erica Tavares, Diana M Sobieraj, Jennifer N. Clements, Joseph Bubalo, Margarita V. DiVall, Robert J. Cersosimo and Daniel M. Witt. Their work appears in journals such as Journal of Oncology Practice and The Psychiatric times.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.